Clinical Trials
2 trialsNCT07569926 2026-06-02
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
Blue Earth Diagnostics
Phase 4 Not yet recruiting
NCT05722925 2025-11-14
Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET
OHSU Knight Cancer Institute
Phase 4 Active not recruiting